Home › NDC Lookup › Ingredients › Baclofen › 72888-0010-05
BACLOFEN 10 mg Tablet, 500-count — NDC 72888-0010-05 package photo

BACLOFEN 10 mg Tablet, 500-count

by Advagen Pharma Limited · 500 TABLET in 1 BOTTLE (72888-010-05)
NDC 72888-0010-05
🏷️ FDA NDC (as labeled) 72888-010-05 billing pads the product segment with a zero
This package
Contains500-count Cost per ea$0.0315 NADAC Per package$15.75 / 500 tablets Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.1417/unit · Part D plans $0.1147/unit — full pricing hub ↓
Also comes in: 100 tablets 72888-0010-01 1000 tablets 72888-0010-00
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Baclofen (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Nov 26, 2025 — Presence of Foreign Tablets/Capsules (Golden State Medical Supply Inc.) · FDA recall D-0235-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

🆔 Identity & classification

FDA NDC (as labeled) 72888-010-05
Product NDC 72888-010
11-digit billing NDC 72888001005
NCPDP billing unit EA — each (per item)
RxCUI 197391, 197392, 430902, 2679605
UNII H789N3FKE8
UPC 0372888009018, 0372888010007, 0372888010014, 0372888202051 +8 more
Application # ANDA209102
SPL Set ID 04dac0f6-cc6c-4959-9bca-a6e4a99690f3
Established class (EPC) gamma-Aminobutyric Acid-ergic Agonist
Mechanism of action GABA A Agonists; GABA B Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2018-04-01
Route ORAL
Dosage form TABLET
Substance BACLOFEN
GPI-14 75100010000305
GPI class Baclofen
GCN Seq No 004679
GCN 18010
HICL code 001949
Ingredient (HICL) Baclofen
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H6
Therapeutic class — intermediate (HIC2) Drugs Acting Principally On The Midbrain
HIC3 code H6H
Therapeutic class — specific (HIC3) Skeletal Muscle Relaxants
AHFS code 12:20.12.00
AHFS class Gaba-Derivative Skeletal Muscle Relaxant
FDB label name BACLOFEN 10 MG TABLET
FDB brand name Baclofen
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AB · RLD · RS
Why two NDCs? The FDA registers this code as 72888-010-05 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 72888-0010-05. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the gamma-Aminobutyric Acid-ergic Agonist class.

Pharmacologic class gamma-Aminobutyric Acid-ergic Agonist
Drug family (ATC) Other centrally acting agents
How it works GABA B Agonists, GABA A Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerAdvagen Pharma Limited
Application holderRUBICON RESEARCH LTD
FDA applicationANDA209102 (ANDA)
Labeler code72888
First marketedApr 2018
Product typeHuman Prescription Drug
Portfolio78 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name BACLOFEN 10 MG TABLET Ingredient Baclofen
📖 What it is MedlinePlus · NLM

Baclofen is used to treat pain and certain types of spasticity (muscle stiffness and tightness) from multiple sclerosis, spinal cord injuries, or other spinal cord diseases. Baclofen is in a class of medications called skeletal muscle relaxants. Baclofen acts on the spinal cord nerves and decreases the number and severity of muscle spasms caused by multiple sclerosis or spinal cord conditions. It also relieves pain and improves muscle movement.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Baclofen is prescribed to reduce spasticity — the muscle stiffness, spasms, and rigidity that come with conditions like multiple sclerosis or spinal cord injury. Oral forms are als...
  • What exactly is baclofen being used to treat — and will it help my pain too?
  • Yes, and this is really important. Stopping baclofen suddenly — especially the pump form — can cause a dangerous withdrawal reaction: your spasticity can return much worse than bef...
  • I heard you can't just stop taking baclofen — is that really true?
📖 Read our full Baclofen guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color white
ShapeRound
Imprint025
Size9 mm
ScoringScored — splits in 2
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII 5856J3G2A2
    A starch-based powder made from potatoes and processed with sodium. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the medicine can be absorbed.
  • UNII O8232NY3SJ
    A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.

5 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.032 $15.75 / 500 tablets
Medicaid paysCMS SDUD · 12 mo $0.1417 $70.85 / 500 tablets
Medicare drug plans payPart D · Q2 2026 $0.1147 $57.35 / 500 tablets
NADAC price history (per ea) — tap or hover for the price & month
Dec 2021 Jul 2022 Dec 2025 Aug 2026 $0.069 $0.032
▼ Down 49% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Baclofen 10 mg 00172-4096-60 Teva 100 tablets $0.031 AB Availability likely —
Baclofen 10 mg 00527-1330-01 Lannett 100 tablets $0.031 — Availability likely —
Baclofen 10 mg 00603-2406-21 Par 100 tablets $0.031 AB Availability likely —
Baclofen 10 mg 00832-1054-10 Upsher-Smith 1000 tablets $0.031 AB Availability likely —
Baclofen 10 mg 00904-6475-61 Major 100 tablets $0.031 — Availability likely —
Baclofen 10 mg 00904-7552-61 Major 100 tablets $0.031 AB Availability likely —
Baclofen 10 mg 16571-0171-01 Rising 100 tablets $0.031 AB Availability likely —
Baclofen 10 mg 16714-0071-04 Northstar 100 tablets $0.031 AB Availability likely —
Baclofen 10 mg 29300-0343-01 Unichem 100 tablets $0.031 AB Availability likely —
Baclofen 10 mg 50268-0106-15 AvPAK 50 tablets $0.031 AB Availability likely —
Baclofen 10 mg 52817-0320-00 TruPharma 1000 tablets $0.031 AB Availability likely —
Baclofen 10 mg 58657-0731-01 Method 100 tablets $0.031 AB Availability likely —
Baclofen 10 mg 58657-0931-01 Method 100 tablets $0.031 AB Availability likely —
Baclofen 10 mg 59651-0394-01 Aurobindo 100 tablets $0.031 AB Availability likely —
Baclofen 10 mg 60687-0815-01 American 100 tablets $0.031 AB Availability likely —
Baclofen 10 mg 62135-0473-05 Chartwell 500 tablets $0.031 AB Availability likely —
Baclofen 10 mg 70512-0782-10 SOLA 100 tablets $0.031 AB Availability likely —
Baclofen 10 mg 70710-1285-00 Zydus 1000 tablets $0.031 AB Availability likely —
Baclofen 10 mg 70756-0288-11 Lifestar 100 tablets $0.031 AB Availability likely —
Baclofen 10 mg 71930-0006-12 Eywa 100 tablets $0.031 AB Availability likely —
Baclofen 10 mgthis 72888-0010-05 Advagen 500 tablets $0.031 AB Availability likely —
Baclofen 10 mg 00615-8466-05 NCS 15 tablets — AB FDA listed —
Baclofen 10 mg 10135-0532-01 Marlex 100 tablets — AB FDA listed —
Baclofen 10 mg 42571-0428-01 Micro 100 tablets — AB Discontinued —
Baclofen 10 mg 43063-0864-30 PD-Rx 30 tablets — — FDA listed —
Baclofen 10 mg 50090-6149-00 A-S 60 tablets — AB FDA listed —
Baclofen 10 mg 50090-6868-00 A-S 60 tablets — AB FDA listed —
Baclofen 10 mg 50090-6869-00 A-S 90 tablets — AB FDA listed —
Baclofen 10 mg 50090-7600-00 A-S 60 tablets — AB FDA listed —
Baclofen 10 mg 50090-7601-00 A-S 90 tablets — AB FDA listed —
Baclofen 10 mg 50090-7913-00 A-S 90 tablets — AB FDA listed —
Baclofen 10 mg 50090-7928-00 A-S 90 tablets — AB FDA listed —
Baclofen 10 mg 51407-0973-01 Golden 100 tablets — AB FDA listed —
Baclofen 10 mg 55154-0198-00 Cardinal 10 tablets — AB FDA listed —
Baclofen 10 mg 55154-7635-00 Cardinal 10 tablets — — FDA listed —
Baclofen 10 mg 55289-0757-30 PD-Rx 30 tablets — AB FDA listed —
Baclofen 10 mg 63187-0147-30 Proficient 30 tablets — AB FDA listed —
Baclofen 10 mg 63187-0313-20 Proficient 20 tablets — AB FDA listed —
Baclofen 10 mg 63629-1224-01 Bryant 1000 tablets — AB FDA listed —
Baclofen 10 mg 63629-1225-01 Bryant 100 tablets — AB FDA listed —
Baclofen 10 mg 63629-2080-01 Bryant 1000 tablets — — FDA listed —
Baclofen 10 mg 63629-2081-01 Bryant 1000 tablets — — FDA listed —
Baclofen 10 mg 63629-2082-01 Bryant 100 tablets — — FDA listed —
Baclofen 10 mg 63629-2128-01 Bryant 100 tablets — AB FDA listed —
Baclofen 10 mg 67046-1072-03 Coupler 30 tablets — AB FDA listed —
Baclofen 10 mg 67296-1947-03 Redpharm 30 tablets — AB FDA listed —
Baclofen 10 mg 67296-2259-03 Redpharm 30 tablets — AB FDA listed —
Baclofen 10 mg 67544-0671-60 Aphena 90 tablets — — FDA listed —
Baclofen 10 mg 68071-2289-03 NuCare 3 tablets — AB FDA listed —
Baclofen 10 mg 68071-3407-03 NuCare 3 tablets — AB FDA listed —
Baclofen 10 mg 68071-3468-06 NuCare 60 tablets — AB Discontinued —
Baclofen 10 mg 68071-3700-03 NuCare 30 tablets — AB FDA listed —
Baclofen 10 mg 68788-8584-01 Preferred 100 tablets — AB FDA listed —
Baclofen 10 mg 68788-8726-01 Preferred 100 tablets — AB FDA listed —
Baclofen 10 mg 68788-8783-01 Preferred 100 tablets — AB FDA listed —
Baclofen 10 mg 68788-9246-01 Preferred 100 tablets — — FDA listed —
Baclofen 10 mg 70518-3089-00 REMEDYREPACK 30 tablets — AB FDA listed —
Baclofen 10 mg 70518-3614-00 REMEDYREPACK 30 tablets — AB Discontinued —
Baclofen 10 mg 70518-4249-00 REMEDYREPACK 30 tablets — AB FDA listed —
Baclofen 10 mg 70518-4384-00 REMEDYREPACK 90 tablets — AB FDA listed —
Baclofen 10 mg 70771-1448-00 Zydus 1000 tablets — AB FDA listed —
Baclofen 10 mg 71205-0474-14 Proficient 14 tablets — — FDA listed —
Baclofen 10 mg 71335-0344-00 Bryant 112 tablets — — Discontinued —
Baclofen 10 mg 71335-1797-00 Bryant 112 tablets — AB FDA listed —
Baclofen 10 mg 71335-2392-00 Bryant 112 tablets — AB FDA listed —
Baclofen 10 mg 71335-2767-00 Bryant 112 tablets — AB FDA listed —
Baclofen 10 mg 71335-2826-01 Bryant 100 tablets — AB FDA listed —
Baclofen 10 mg 71335-9638-00 Bryant 112 tablets — AB FDA listed —
Baclofen 10 mg 71335-9759-00 Bryant 112 tablets — AB FDA listed —
Baclofen 10 mg 71610-0452-60 Aphena 90 tablets — — FDA listed —
Baclofen 10 mg 71610-0660-60 Aphena 90 tablets — AB FDA listed —
Baclofen 10 mg 71610-0924-53 Aphena 60 tablets — AB FDA listed —
Baclofen 10 mg 72162-1079-08 Bryant 140 tablets — — FDA listed —
Baclofen 10 mg 72162-1152-01 Bryant 100 tablets — — FDA listed —
Baclofen 10 mg 72162-2373-00 Bryant 1000 tablets — AB FDA listed —
Baclofen 10 mg 72162-2449-00 Bryant 1000 tablets — AB FDA listed —
Baclofen 10 mg 72789-0479-01 PD-Rx 100 tablets — AB FDA listed —
Baclofen 10 mg 72789-0508-30 PD-Rx 30 tablets — AB FDA listed —
Baclofen 10 mg 72865-0297-01 XLCare 100 tablets — AB FDA listed —
Baclofen 10 mg 76420-0241-30 Asclemed 30 tablets — AB FDA listed —
Baclofen 10 mg 76420-0357-00 Asclemed 1000 tablets — AB FDA listed —
Baclofen 10 mg 80425-0080-02 Advanced 60 tablets — AB FDA listed —
Baclofen 10 mg 80425-0156-01 Advanced 30 tablets — AB FDA listed —
Baclofen 10 mg 80425-0391-01 Advanced 30 tablets — AB FDA listed —
Baclofen 10 mg 80425-0568-01 Advanced 30 tablets — AB FDA listed —
Baclofen 10 mg 82461-0717-10 Medcore 100 tablets — AB FDA listed —
Baclofen 10 mg 82804-0242-20 Proficient 20 tablets — AB FDA listed —
Baclofen 10 mg 82868-0013-30 Northwind 30 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2018
On the market since
Apr 2018
📍
2026
Currently FDA-listed
8 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 72888-0010-05, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
128.9K
Units reimbursed last 4 qtrs
9.6M
Gross reimbursed last 4 qtrs
$1.36M
Avg / prescription
$10.56
Avg / unit
$0.1417
Latest quarter Q4 2025
32.6KRx
Medicaid pays / ea
$0.1417
gross reimbursed
vs
NADAC / ea
$0.0315
acquisition cost
=
Spread
+$0.1102
+350% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
40% FFS 60% MCO
Fee-for-service · 51,089 Rx Managed care · 77,816 Rx
State Medicaid map
Alaska: 25,560 units · 3,487 per 100k residents AK Maine: 75,481 units · 5,411 per 100k residents ME Washington: 188,894 units · 2,418 per 100k residents WA Idaho: 90,514 units · 4,609 per 100k residents ID Montana: 42,605 units · 3,764 per 100k residents MT North Dakota: no data reported ND Minnesota: 135,250 units · 2,358 per 100k residents MN Wisconsin: 211,733 units · 3,583 per 100k residents WI Michigan: 253,965 units · 2,530 per 100k residents MI New York: 386,059 units · 1,973 per 100k residents NY Vermont: 12,557 units · 1,941 per 100k residents VT New Hampshire: 42,470 units · 3,029 per 100k residents NH Oregon: 278,202 units · 6,572 per 100k residents OR Nevada: 127,086 units · 3,979 per 100k residents NV Wyoming: 22,992 units · 3,937 per 100k residents WY South Dakota: 23,058 units · 2,509 per 100k residents SD Iowa: 115,757 units · 3,610 per 100k residents IA Illinois: 301,303 units · 2,401 per 100k residents IL Indiana: 369,260 units · 5,381 per 100k residents IN Ohio: 377,418 units · 3,203 per 100k residents OH Pennsylvania: 362,073 units · 2,794 per 100k residents PA New Jersey: 52,776 units · 568 per 100k residents NJ Massachusetts: 56,200 units · 803 per 100k residents MA California: 980,451 units · 2,516 per 100k residents CA Utah: 93,813 units · 2,745 per 100k residents UT Colorado: 263,610 units · 4,485 per 100k residents CO Nebraska: 82,499 units · 4,171 per 100k residents NE Missouri: 580,022 units · 9,361 per 100k residents MO Kentucky: 295,261 units · 6,524 per 100k residents KY West Virginia: 99,411 units · 5,616 per 100k residents WV Virginia: 418,286 units · 4,799 per 100k residents VA Maryland: 77,342 units · 1,251 per 100k residents MD Connecticut: 40,247 units · 1,113 per 100k residents CT Rhode Island: 5,996 units · 548 per 100k residents RI Arizona: 274,529 units · 3,694 per 100k residents AZ New Mexico: 271,515 units · 12,844 per 100k residents NM Kansas: 76,093 units · 2,588 per 100k residents KS Arkansas: 188,804 units · 6,156 per 100k residents AR Tennessee: 147,803 units · 2,074 per 100k residents TN North Carolina: 428,303 units · 3,953 per 100k residents NC South Carolina: 101,558 units · 1,890 per 100k residents SC Delaware: 15,292 units · 1,483 per 100k residents DE Oklahoma: 290,410 units · 7,165 per 100k residents OK Louisiana: 238,948 units · 5,224 per 100k residents LA Mississippi: 118,811 units · 4,041 per 100k residents MS Alabama: 100,055 units · 1,959 per 100k residents AL Georgia: 217,737 units · 1,974 per 100k residents GA D.C.: 4,266 units · 628 per 100k residents DC Hawaii: 3,007 units · 210 per 100k residents HI Texas: 370,908 units · 1,216 per 100k residents TX Florida: 263,182 units · 1,164 per 100k residents FL
Units reimbursed · per 100k residents
21012,844
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New Mexico 12,844 /100k
2 Missouri 9,361 /100k
3 Oklahoma 7,165 /100k
4 Oregon 6,572 /100k
5 Kentucky 6,524 /100k
6 Arkansas 6,156 /100k
7 West Virginia 5,616 /100k
8 Maine 5,411 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1000 tablets72888-0010-00 164,716 Rx · $1,811,278
500 tablets this page72888-0010-05 128,905 Rx · $1,361,019
100 tablets72888-0010-01 117,691 Rx · $1,278,278
Drug total (last 4 qtrs): 411,312 Rx · 30,916,193 units · $4,450,575 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Baclofen — the program that covers self-administered drugs. 23 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Baclofen. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$22.67M
Claims incl. refills
1.3M
Beneficiaries
744.4K
Spend / beneficiary
$30.45
Spend / claim
$17.31
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Baclofen — the ingredient across all brands.

Top reported reactions

Fatigue6,296
Pain5,852
Fall5,569
Nausea4,756
Headache4,525
Gait Disturbance4,179
Dizziness3,650

Reporter sex

0 reports
Male · 34%
Female · 66%
Unknown · 0%

Serious outcomes

Hospitalization28,757
Death6,566
Life-threatening2,815
Disabling2,171
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 6,707 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
72888-0010-00 1000 TABLET in 1 BOTTLE (72888-010-00) $0.0315 / ea $31.48 2018-04-01 Active
72888-0010-01 100 TABLET in 1 BOTTLE (72888-010-01) $0.0315 / ea $3.15 2018-04-01 Active
72888-0010-05 You're viewing this 500 TABLET in 1 BOTTLE (72888-010-05) $0.0315 / ea $15.74 2018-04-01 Active

You're viewing one of 3 pack sizes for this product.

This pack effectively ties for the lowest per-ea cost of the 3 priced pack sizes ($0.0315 NADAC).

This pack accounts for about 31% of this product's recent Medicaid fills; the largest share goes to the 1000 tablets pack. See all packs ↓

Pack size FAQ

What quantity is in NDC 72888-0010-05?
NDC 72888-0010-05 is a 500-count package — 500 tablet in 1 bottle.
What is the difference between NDC 72888-0010-05 and NDC 72888-0010-01?
Both are BACLOFEN 10 mg Tablet — the drug itself is identical. NDC 72888-0010-05 is the 500-count package, while NDC 72888-0010-01 is the 100 tablets package.
What NDC number is used to bill for this package of BACLOFEN 10 mg Tablet?
Bill NDC 72888-0010-05 — the 11-digit billing format is 72888001005. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description
🎯 Indications and Usage 111 words ▾

INDICATIONS AND USAGE Baclofen tablets, USP are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen tablets, USP may also be of some value in patients with spinal cord injuries and other spinal cord diseases.

Baclofen tablets, USP are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson's disease has not been established and, therefore, it is not recommended for these conditions.

⏱️ Dosage and Administration 119 words ▾

DOSAGE AND ADMINISTRATION The determination of optimal dosage requires individual titration. Start therapy at a low dosage and increase gradually until optimum effect is achieved (usually between 40-80 mg daily). The following dosage titration schedule is suggested: 5 mg t.i.d. for 3 days 10 mg t.i.d. for 3 days 15 mg t.i.d. for 3 days 20 mg t.i.d. for 3 days Thereafter additional increases may be necessary but the total daily dose should not exceed a maximum of 80 mg daily (20 mg q.i.d.).

The lowest dose compatible with an optimal response is recommended. If benefits are not evident after a reasonable trial period, patients should be slowly withdrawn from the drug (See WARNINGS , Abrupt Drug Withdrawal ).

⛔ Contraindications 4 words ▾

CONTRAINDICATIONS Hypersensitivity to baclofen.

⚠️ Warnings ~1 min read ▾

WARNINGS a. Neonatal Withdrawal Symptoms: Withdrawal symptoms have been reported starting hours to days after delivery in neonates whose mothers were treated with oral baclofen throughout pregnancy. The symptoms of withdrawal in these infants have included increased muscle tone, tremor, jitteriness, and seizure.

If the potential benefit justifies the potential risk to the fetus and oral baclofen is continued during pregnancy, gradua ly reduce the dose and discontinue baclofen before delivery. If slow withdrawal is not feasible, advise the parents or caregivers of the potential for neonatal withdrawal. b. Abrupt Drug Withdrawal: Hallucinations and seizures have occurred on abrupt withdrawal of baclofen.

Therefore, except for serious adverse reactions, the dose should be reduced slowly when the drug is discontinued. c. Impaired Renal Function: Because baclofen is primarily excreted unchanged through the kidneys, it should be given with caution, and it may be necessary to reduce the dosage. d. Stroke: Baclofen has not significantly benefited patients with stroke.

These patients have also shown poor tolerability to the drug. e. Pregnancy: Baclofen has been shown to increase the incidence of omphaloceles (ventral hernias) in fetuses of rats given approximately 13 times the maximum dose recommended for human use, at a dose which caused significant reductions in food intake and weight gain in dams. This abnormality was not seen in mice or rabbits.

There was also an increased incidence of incomplete sternebral ossification in fetuses of rats given approximately 13 times the maximum recommended human dose, and an increased incidence of unossified phalangeal nuclei of forelimbs and hindlimbs in fetuses of rabbits given approximately 7 times the maximum recommended human dose. In mice, no teratogenic effects were observed, although reductions in mean fetal weight with consequent delays in skeletal ossification were present when dams were given 17 and 34 times the human daily dose.

There are no studies in pregnant women. Baclofen should be used during pregnancy only if the benefit clearly justifies the potential risk to the fetus.

🤒 Adverse Reactions 215 words ▾

ADVERSE REACTIONS The most common is transient drowsiness (10 to 63%). In one controlled study of 175 patients, transient drowsiness was observed in 63% of those receiving baclofen compared to 36% of those in the placebo group. Other common adverse reactions are dizziness (5 to 15%), weakness (5 to 15%) and fatigue (2 to 4%).

Others reported: Neuropsychiatric: Confusion (1 to 11%), headache (4 to 8%), insomnia (2 to 7%); and, rarely, euphoria, excitement, depression, hallucinations, paresthesia, muscle pain, tinnitus, slurred speech, coordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizure. Cardiovascular: Hypotension (0 to 9%). Rare instances of dyspnea, palpitation, chest pain, syncope.

Gastrointestinal: Nausea (4 to 12%), constipation (2 to 6%); and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhea, and positive test for occult blood in stool. Genitourinary: Urinary frequency (2 to 6%); and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, hematuria. Other: Instances of rash, pruritus, ankle edema, excessive perspiration, weight gain, nasal congestion.

Some of the CNS and genitourinary symptoms may be related to the underlying disease rather than to drug therapy. The following laboratory tests have been found to be abnormal in a few patients receiving baclofen: increased SGOT, elevated alkaline phosphatase, and elevation of blood sugar.

🆘 Overdosage 58 words ▾

OVERDOSAGE Signs and Symptoms: Vomiting, muscular hypotonia, drowsiness, accommodation disorders, coma, respiratory depression and seizures. Treatment: In the alert patient, empty the stomach promptly by induced emesis followed by lavage. In the obtunded patient, secure the airway with a cuffed endotracheal tube before beginning lavage (do not induce emesis). Maintain adequate respiratory exchange, do not use respiratory stimulants.

🧬 Clinical Pharmacology 147 words ▾

CLINICAL PHARMACOLOGY The precise mechanism of action of baclofen is not fully known. Baclofen is capable of inhibiting both monosynaptic and polysynaptic reflexes at the spinal level, possibly by hyperpolarization of afferent terminals, although actions at supraspinal sites may also occur and contribute to its clinical effect. Although baclofen is an analog of the putative inhibitory neurotransmitter gamma-aminobutyric acid (GABA), there is no conclusive evidence that actions on GABA systems are involved in the production of its clinical effects.

In studies with animals baclofen has been shown to have general CNS depressant properties as indicated by the production of sedation with tolerance, somnolence, ataxia, and respiratory and cardiovascular depression. Baclofen is rapidly and extensively absorbed and eliminated. Absorption may be dose-dependent, being reduced with increasing doses.

Baclofen is excreted primarily by the kidney in unchanged form and there is relatively large intersubject variation in absorption and/or elimination.

📦 How Supplied / Storage and Handling ~1 min read ▾

HOW SUPPLIED Baclofen Tablets, USP 5 mg are available as a White to off white, round flat-faced, beveled edge tablets debossed with "023" on one side and plain on other side, containing 5 mg baclofen USP packaged in bottles of 100 and 500 tablets. NDC 72888-009-01 100s count NDC 72888-009-05 500s count Baclofen Tablets, USP 10 mg are available as a White to off white, round flat-faced, beveled edge tablets debossed with "024" on one side and score on other side, containing 10 mg baclofen USP packaged in bottles of 100, 500 and 1000 tablets.

NDC 72888-010-01 100s count NDC 72888-010-05 500s count NDC 72888-010-00 1000s count Baclofen Tablets, USP 15 mg are available as a White to off white, round flat-faced, beveled edge tablets debossed with "˄B1" on one side and plain on the other side, containing 15 mg baclofen USP packaged in bottles of 30, 100, 500 and 1000 tablets. NDC 72888-202-30 30s count NDC 72888-202-01 100s count NDC 72888-202-05 500s count NDC 72888-202-00 1000s count Baclofen Tablets, USP 20 mg are available as a White to off white, round flat-faced, beveled edge tablets debossed with "025" on one side and score on other side, containing 20 mg baclofen USP packaged in bottles of 100, 500 and 1000 tablets.

NDC 72888-011-01 100s count NDC 72888-011-05 500s count NDC 72888-011-00 1000s count PHARMACIST: Dispense in a well closed container as defined in the USP, with a child-resistant closure (as required). Store at 20° to 25°C (68°to 77°F) [See USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Distributed by: Advagen Pharma Ltd East Windsor, NJ 08520, USA Manufactured by: Rubicon Research Limited, Thane, 421506 India. Rev: 01/2026

📋 Description 96 words ▾

DESCRIPTION Baclofen, USP is a muscle relaxant and antispastic. Its chemical name is 4-amino-3-(4-chlorophenyl)-butanoic acid. The structural formula is: C 10 H 12 ClNO 2 M.W.

213.66 Baclofen, USP is a white to off-white odorless or practically odorless crystalline powder. It is slightly soluble in water, very slightly soluble in methanol and insoluble in chloroform. Each tablet, for oral administration, contains 5 mg, 10 mg, 15 mg or 20 mg baclofen, USP.

In addition, each tablet contains the following inactive ingredients: Microcrystalline Cellulose, Pregelatinized Starch, Sodium Starch Glycolate, Colloidal Silicon dioxide and Magnesium Stearate. Chemical Structure

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 72888-0009-01 · Advagen 72888-0011-00 · Advagen →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.